Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Saumya Das
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
LQT Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Das owns equity in LQT Therapeutics, a privately held company focused on developing new therapies to treat congenital long QT syndrome. LQT Therapeutics has two programs in development – 2MMB and SKG-1. The goal of the research is to explore a recently discovered new therapy that may ultimately be a new treatment to eliminate the risk of sudden death in long QT patients. The research project studies 2MMB and may also further validate the SKG-1 approach in cell culture/animal models. New data from this grant may be of interest to LQT therapeutics. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Novel Therapy for Long QT Syndrome
Narrative Congenital long QT syndrome (LQTS) is an inherited disease that affects otherwise healthy individuals and carries an increased risk of sudden death due to cardiac arrhythmia. Current treatments do not completely reduce this risk of sudden death. This proposal aims to explore a recently discovered new therapy that may ultimately be a new treatment to eliminate the risk of sudden death in long QT patients. �
Filed on February 05, 2019.
Tell us what you know about Saumya Das's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Saumya Das filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Saumya Das | Massachusetts General Hospital | Conflict of Interest | Dyrnamix | Value cannot be readily determined |
| Saumya Das | Massachusetts General Hospital | Conflict of Interest | Dyrnamix | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.